Franklin Resources
ELVN icon

Franklin Resources’s Enliven Therapeutics ELVN Stock Holding History

Franklin Resources’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Buy
31,163
+10,981
+54% +$466K ﹤0.01% 2095
2026
Q1 		$791K Buy
20,182
+15
+0.1% +$416 ﹤0.01% 2279
2025
Q4 		$311K Sell
20,167
-410,073
-95% -$8.17M ﹤0.01% 2608
2025
Q3 		$8.81M Hold
430,240
– – ﹤0.01% 1209
2025
Q2 		$8.63M Buy
430,240
+410,034
+2,029% +$7.76M ﹤0.01% 1179
2025
Q1 		$398K Buy
20,206
+55
+0.3% +$1.18K ﹤0.01% 2360
2024
Q4 		$453K Hold
20,151
– – ﹤0.01% 2333
2024
Q3 		$559K Buy
+20,151
New +$467K ﹤0.01% 2235
2023
Q3 		– Sell
-11,685
Closed -$238K – 2703
2023
Q2 		$238K Buy
+11,685
New +$236K ﹤0.01% 2306

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Franklin Resources's ELVN Position: Q2 2026 in Review

Franklin Resources increased its Enliven Therapeutics (ELVN) stake by 54% in Q2 2026, buying an estimated $466K and bringing the position to 31,163 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2095.

Franklin Resources first reported a position in ELVN in Q2 2023 and has held it in 9 quarters since. The position peaked at $8.81M in Q3 2025. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Franklin Resources held 31,163 shares of Enliven Therapeutics worth $1.58M as of Q2 2026.
  • Franklin Resources bought 10,981 Enliven Therapeutics shares in Q2 2026, an estimated $466K.
  • Enliven Therapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2095 holding.
  • Franklin Resources first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 9 quarters since.
  • Franklin Resources's Enliven Therapeutics position peaked at $8.81M in Q3 2025.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.